Wed, 29th Jul 2020 19:01
Avacta Group PLC - Wetherby-based biotherapeutics firm - Expands partnership with Daewoong Pharmaceutical Co Ltd and joint venture AffyXell Therapeutics for development of stem cell treatments including Avacta's Affimer therapy for treating seriously ill patients with Covid-19.
Current stock price: 145.50 pence
Year-to-date change: eightfold rise from 17.25p
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:
Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company developing cancer treatments and diagnostics - Promotes Christina Coughlin to ...
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Avacta Group (AVCT)